- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01239732
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer
3 maj 2016 uppdaterad av: Hoffmann-La Roche
Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma
This open-label, non-comparative, multi-center study will assess the safety profile and efficacy of Avastin (bevacizumab) when added to carboplatin and paclitaxel therapy in participants with epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma.
Participants will receive 15 milligrams/kilogram (mg/kg) Avastin intravenously (IV) on Day 1 of every cycle for up to 36 cycles of 3 weeks each, carboplatin (area under the plasma concentration-time curve [AUC] 5-6 mg/ml/min) on Day 1 every 3 weeks for a maximum of 8 cycles and paclitaxel 175 milligram per square meter (mg/m^2) on Day 1 every 3 weeks or 80 mg/m^2 every week for a maximum of 8 cycles.
The anticipated time on study drug will be 108 weeks or until disease progression or unacceptable toxicity.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
1021
Fas
- Fas 3
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Buenos Aires, Argentina, C1199ACI
-
Buenos Aires, Argentina, C1280AEB
-
Buenos Aires, Argentina, C1426ANZ
-
Rosario, Argentina, S2002KDS
-
Tucuman, Argentina, T4000IAK
-
-
-
-
BA
-
Salvador, BA, Brasilien, 41950-610
-
-
CE
-
Fortaleza, CE, Brasilien, 60125-120
-
-
GO
-
Goiania, GO, Brasilien, 74605-070
-
-
PR
-
Curitiba, PR, Brasilien, 80530-010
-
-
RJ
-
Rio de Janeiro, RJ, Brasilien, 20230-130
-
-
RS
-
Porto Alegre, RS, Brasilien, 90430-090
-
Porto Alegre, RS, Brasilien, 90020-090
-
-
SP
-
Piracicaba, SP, Brasilien, 13419-155
-
Sao Paulo, SP, Brasilien, 01246-000
-
Sao Paulo, SP, Brasilien, 01308-050
-
Sao Paulo, SP, Brasilien, 01317-000
-
Sao Paulo, SP, Brasilien, 01509-010
-
-
-
-
-
Sofia, Bulgarien, 1756
-
Varna, Bulgarien, 9010
-
Veliko Tarnovo, Bulgarien, 5000
-
-
-
-
-
Aalborg, Danmark, 9000
-
Roskilde, Danmark, 4000
-
Vejle, Danmark, 7100
-
-
-
-
-
Cairo, Egypten, 11555
-
Tanta, Egypten
-
-
-
-
-
Tallinn, Estland, 11312
-
Tallinn, Estland, 13419
-
Tartu, Estland, 50406
-
-
-
-
-
Amiens, Frankrike, 80090
-
Bordeaux, Frankrike, 33076
-
Brest, Frankrike, 29200
-
Caen, Frankrike, 14076
-
Clermont Ferrand, Frankrike, 63011
-
Grenoble, Frankrike, 38028
-
Lille, Frankrike, 59020
-
Lyon, Frankrike, 69373
-
Marseille, Frankrike, 13273
-
Mougins, Frankrike, 06250
-
Paris, Frankrike, 75970
-
Paris, Frankrike, 75908
-
Paris, Frankrike, 75651
-
Paris, Frankrike, 75674
-
Paris, Frankrike, 75231
-
Paris, Frankrike, 75571
-
Reims CEDEX, Frankrike, 51056
-
Strasbourg, Frankrike, 67065
-
Toulouse, Frankrike, 31059
-
Villejuif, Frankrike, 94805
-
-
-
-
-
Athens, Grekland, 11527
-
Athens, Grekland, 115 28
-
Athens, Grekland, 145 64
-
Heraklion, Crete, Grekland, 71110
-
Larissa, Grekland, 41 110
-
Patras, Grekland, 265 00
-
Thessaloniki, Grekland, 56429
-
-
-
-
-
Hong Kong, Hong Kong
-
Hong Kong, Hong Kong, 852
-
-
-
-
-
Bangalore, Indien, 560017
-
Bangalore, Indien, 560054
-
Hyderabad, Indien, 650034
-
Jaipur, Indien, 302013
-
Kochi, Indien, 682304
-
New Delhi, Indien, 110029
-
Pune, Indien, 411004
-
-
-
-
-
Dublin, Irland, 7
-
-
-
-
-
Afula, Israel, 18101
-
Beer Sheva, Israel, 8410101
-
Haifa, Israel, 34362
-
Haifa, Israel, 31096
-
Holon, Israel, 58100
-
Jerusalem, Israel, 91120-01
-
Jerusalem, Israel, 9372212
-
Kfar Saba, Israel, 44281
-
Petach Tikva, Israel, 49100
-
Ramat Gan, Israel, 52621
-
Rehovot, Israel, 7610001
-
Tel Aviv, Israel, 64239-06
-
-
-
-
Campania
-
Napoli, Campania, Italien, 80131
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Italien, 40138
-
Meldola, Emilia-Romagna, Italien, 47014
-
-
Lazio
-
Roma, Lazio, Italien, 00128
-
Roma, Lazio, Italien, 00157
-
-
Liguria
-
Genova, Liguria, Italien, 16128
-
-
Lombardia
-
Brescia, Lombardia, Italien, 25123
-
Milano, Lombardia, Italien, 20162
-
Milano, Lombardia, Italien, 20141
-
Monza, Lombardia, Italien, 20052
-
Saronno, Lombardia, Italien, 21047
-
-
Piemonte
-
Novara, Piemonte, Italien, 28100
-
Torino, Piemonte, Italien, 10126
-
Torino, Piemonte, Italien, 10128
-
-
Sicilia
-
Palermo, Sicilia, Italien, 90146
-
-
Toscana
-
Firenze, Toscana, Italien, 50139
-
Pisa, Toscana, Italien, 56126
-
-
Umbria
-
Perugia, Umbria, Italien, 06123
-
Terni, Umbria, Italien, 05100
-
-
-
-
-
Ankara, Kalkon, 06500
-
Ankara, Kalkon, 06230
-
Diyarbakir, Kalkon, 10000
-
Istanbul, Kalkon, 34390
-
-
-
-
-
Quebec, Kanada, G1R 3S1
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 4N2
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1H 8L6
-
Toronto, Ontario, Kanada, M5G 2M9
-
-
Quebec
-
Montreal, Quebec, Kanada, H2L 4M1
-
-
-
-
-
Shuwaikh, Kuwait, 70653
-
-
-
-
-
Daugavpils, Lettland, 5417
-
Riga, Lettland, LV-1002
-
Riga, Lettland, LV 1079
-
-
-
-
-
Kaunas, Litauen, 50009
-
Klaipeda, Litauen, 92288
-
Vilnius, Litauen, 08660
-
-
-
-
-
Bitola, Makedonien, fd jugoslaviska republiken, 7000
-
Skopje, Makedonien, fd jugoslaviska republiken, 1000
-
-
-
-
-
Distrito Federal, Mexiko, 14080
-
Oaxaca, Mexiko, 68000
-
Toluca, Mexiko, 50180
-
-
-
-
-
Alkmaar, Nederländerna, 1815 JD
-
Amsterdam, Nederländerna, 1091 AC
-
Apeldoorn, Nederländerna, 7334 DZ
-
Blaricum, Nederländerna, 1261 AN
-
Breda, Nederländerna, 4819 EV
-
Capelle a/d IJssel, Nederländerna, NL 2900 AR
-
Den Haag, Nederländerna, 2545 CH
-
Den Haag, Nederländerna, 2512 VA
-
Deventer, Nederländerna, 7416 SE
-
Dordrecht, Nederländerna, 3318 AT
-
Eindhoven, Nederländerna, 5623 EJ
-
Leidschendam, Nederländerna, 2262 BA
-
Rotterdam, Nederländerna, 3045 PM
-
Sittard-Geleen, Nederländerna, 6162 BG
-
Utrecht, Nederländerna, 3582 KE
-
-
-
-
-
Bydgoszcz, Polen, 85-796
-
Warszawa, Polen, 03-242
-
-
-
-
-
Porto, Portugal, 4200-072
-
-
-
-
-
Bucuresti, Rumänien, 022328
-
Cluj Napoca, Rumänien, 400015
-
Iasi, Rumänien, 700106
-
-
-
-
-
Barnaul, Ryska Federationen, 656049
-
Moscow, Ryska Federationen, 115478
-
Obninsk, Kaluzhskaya Region, Ryska Federationen, 249034
-
Saint-Petersburg, Ryska Federationen, 197022
-
Stavropol, Ryska Federationen, 355045
-
UFA, Ryska Federationen, 450054
-
-
-
-
-
Dammam, Saudiarabien, 31444
-
-
-
-
-
Aarau, Schweiz, 5001
-
Baden, Schweiz, 5405
-
Bellinzona, Schweiz, 6500
-
Bern, Schweiz, 3010
-
Genève 14, Schweiz, 1211
-
Zürich, Schweiz, 8091
-
-
-
-
-
Belgrade, Serbien, 11000
-
Nis, Serbien, 18000
-
-
-
-
-
Bratislava, Slovakien, 833 10
-
Kosice, Slovakien, 04001
-
-
-
-
-
Ljubljana, Slovenien, 1000
-
Maribor, Slovenien, 2000
-
-
-
-
-
Albacete, Spanien, 02006
-
Alicante, Spanien, 3010
-
Badajoz, Spanien, 06080
-
Barcelona, Spanien, 08036
-
Barcelona, Spanien, 08003
-
Barcelona, Spanien, 08906
-
Barcelona, Spanien, 08017
-
Burgos, Spanien, 09006
-
Caceres, Spanien, 10003
-
Castellon, Spanien, 12002
-
Ciudad Real, Spanien, 13005
-
Cordoba, Spanien, 14004
-
Girona, Spanien, 17007
-
Granada, Spanien, 18014
-
Guadalajara, Spanien, 19002
-
Jaen, Spanien, 23007
-
La Coruña, Spanien, 15006
-
Lugo, Spanien, 27003
-
Madrid, Spanien, 28040
-
Madrid, Spanien, 28041
-
Madrid, Spanien, 28007
-
Madrid, Spanien, 28222
-
Madrid, Spanien, 28033
-
Madrid, Spanien, 28002
-
Madrid, Spanien, 28050
-
Malaga, Spanien, 29010
-
Malaga, Spanien, 29011
-
Navarra, Spanien, 31008
-
Salamanca, Spanien, 37007
-
Segovia, Spanien, 40002
-
Sevilla, Spanien, 41014
-
Sevilla, Spanien, 41009
-
Toledo, Spanien, 45004
-
Valencia, Spanien, 46017
-
Valencia, Spanien, 46026
-
Valencia, Spanien, 46009
-
Valencia, Spanien, 46015
-
Valladolid, Spanien, 47010
-
Zaragoza, Spanien, 50009
-
-
Alicante
-
Elda, Alicante, Spanien, 03600
-
-
Asturias
-
Oviedo, Asturias, Spanien, 33011
-
-
Badajoz
-
Llerena (Badajoz), Badajoz, Spanien, 06900
-
-
Barcelona
-
Manresa, Barcelona, Spanien, 08243
-
-
Cadiz
-
Cádiz, Cadiz, Spanien, 11009
-
Jerez de La Frontera, Cadiz, Spanien, 11407
-
-
Guipuzcoa
-
San Sebastian, Guipuzcoa, Spanien, 20080
-
San Sebastian de Los Reyes, Guipuzcoa, Spanien, 28702
-
-
Islas Baleares
-
Palma De Mallorca, Islas Baleares, Spanien, 07014
-
Palma de Mallorca, Islas Baleares, Spanien, 07198
-
-
La Coruña
-
Santiago de Compostela, La Coruña, Spanien, 15706
-
-
Las Palmas
-
Las Palmas de Gran Canaria, Las Palmas, Spanien, 35020
-
-
Madrid
-
Leganes, Madrid, Spanien, 28911
-
-
Tarragona
-
Reus, Tarragona, Spanien, 43204
-
-
Tenerife
-
La Laguna, Tenerife, Spanien, 38320
-
Santa Cruz de Tenerife, Tenerife, Spanien, 38010
-
-
Valencia
-
San Juan, Valencia, Spanien, 03550
-
-
Vizcaya
-
Barakaldo, Vizcaya, Spanien, 48903
-
Bilbao, Vizcaya, Spanien, 48013
-
-
-
-
-
Eskilstuna, Sverige, 63188
-
Falun, Sverige, 79182
-
Karlstad, Sverige, 65185
-
Umeå, Sverige
-
Uppsala, Sverige, 75185
-
Örebro, Sverige, 701 85
-
-
-
-
-
Durban, Sydafrika, 4058
-
Johannesburg, Sydafrika, 2193
-
Sandton, Sydafrika, 2196
-
-
-
-
-
Taipei City, Taiwan, 110
-
Taipei City, Taiwan, 112
-
Taoyuan Hsien, Taiwan, 333
-
-
-
-
-
Budapest, Ungern, 1125
-
Budapest, Ungern, 1122
-
Debrecen, Ungern, 4032
-
Pecs, Ungern, 7624
-
Szeged, Ungern, 6720
-
-
-
-
-
Montevideo, Uruguay, 11600
-
-
-
-
-
Graz, Österrike, 8020
-
Graz, Österrike, 8036
-
Innsbruck, Österrike, 6020
-
Ried-innkreis, Österrike, 4910
-
Salzburg, Österrike, 5020
-
Steyr, Österrike, 4400
-
Villach, Österrike, 9500
-
Wien, Österrike, 1130
-
Wien, Österrike, 1090
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Kvinna
Beskrivning
Inclusion Criteria:
- Histologically confirmed epithelial ovarian carcinoma, fallopian tube carcinoma, primary peritoneal carcinoma or clear cell carcinoma or carcinosarcoma. Participants with recurrent ovarian cancer who have been previously treated with surgery alone for their early stage disease are eligible.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0, 1 or 2
- Life expectancy greater than or equal to (>=3) months
Exclusion Criteria:
- Participants with non-epithelial ovarian cancer, ovarian tumors with low malignant potential (i.e., borderline tumors), or synchronous primary endometrial carcinoma
- Previous systemic therapy for ovarian cancer. Prior neo-adjuvant chemotherapy is allowed
- Planned intraperitoneal cytotoxic chemotherapy
- Radiotherapy within 28 days of Day 1, Cycle 1
- Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to first dose of Avastin
- History or evidence of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade >=1 arterial thromboembolic event or Grade >=3 venous thromboembolic event within 6 months prior to enrollment
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Bevacizumab + Paclitaxel + Carboplatin
Participants will receive bevacizumab 15 mg/kg IV on Day 1 every 3 weeks from Cycle 1 to Cycle 36 (initially concurrent with chemotherapy, then continued as a single agent following the completion of chemotherapy), or until protocol defined disease progression or until unacceptable toxicity (whichever occurred first).
Participants will receive paclitaxel 175 mg/m^2 IV on Day 1 every 3 weeks or 80 mg/m^2 IV every week and carboplatin (AUC 5-6) IV on Day 1 every 3 weeks for a minimum of 4 and maximum of 8 cycles (including up to 4 pre-surgical cycles), or until protocol defined disease progression, or unacceptable toxicity (whichever occurred first).
|
175 mg/m^2 on Day 1 every 3 weeks or at a dose of 80 mg/m^2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
Andra namn:
AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants With at Least One Adverse Event (AE)
Tidsram: Day 1 up to 30 days after last dose of study treatment (until data cutoff 07 December 2014, up to 4 years)
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
|
Day 1 up to 30 days after last dose of study treatment (until data cutoff 07 December 2014, up to 4 years)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Progression-Free Survival (PFS)
Tidsram: Day 1, at end of Cycles 3 and 6, then every 6 cycles while receiving bevacizumab, and then at bevacizumab cessation, every 26 weeks after cessation of bevacizumab until disease progression or death until data cutoff 07 December 2014, up to 4 years
|
PFS was defined as the time between the date of first administration of any study treatment and the date of first documented protocol-defined disease progression (that is [i.e.], radiologically by Response Evaluation Criteria In Solid Tumors [RECIST], clinical, or symptomatic) or death, whichever occurred first.
Participants who had neither progressed nor died at the time of data cut-off (07 December 2014), or participants who were withdrawn from study, or lost to follow-up without documented progression, were censored.
Kaplan-Meier estimation was used for median time to PFS.
|
Day 1, at end of Cycles 3 and 6, then every 6 cycles while receiving bevacizumab, and then at bevacizumab cessation, every 26 weeks after cessation of bevacizumab until disease progression or death until data cutoff 07 December 2014, up to 4 years
|
Percentage of Participants Achieving Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.0
Tidsram: Day 1, at end of Cycles 3 and 6, then every 6 cycles while receiving bevacizumab, and then at bevacizumab cessation, every 26 weeks (Q26W) after cessation of bevacizumab until disease progression or death until data cutoff 07 December 2014, up to 4 years
|
Best overall response (BOR) according to RECIST Version 1.0 was categorized as: CR, PR, progressive disease (PD), stable disease (SD).
CR: disappearance of all target lesions and non-target lesions.
PR: >=30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non-target lesions.
PD: Natural progression or deterioration of the malignancy under study (including new sites of metastasis).
SD: neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started.
Participants with a BOR of CR and PR were defined as responders, while participants with a BOR of SD, PD, or unable to assess were defined as non-responders.
|
Day 1, at end of Cycles 3 and 6, then every 6 cycles while receiving bevacizumab, and then at bevacizumab cessation, every 26 weeks (Q26W) after cessation of bevacizumab until disease progression or death until data cutoff 07 December 2014, up to 4 years
|
Percentage of Participants Achieving an Overall Response by 50% Carcinoma Antigen 125 (CA-125) Response Criteria
Tidsram: 3 days prior to Day 1 of every cycle, then every 6 weeks (Q6W) during the first year, every 3 months (Q3M) in the second and third year, every 6 months (Q6M) in the fourth year of the study (until data cutoff 07 December 2014, up to 4 years)
|
CA-125 responders: Participants with the value of CA-125 reduced by at least 50% and confirmed with a consecutive CA-125 assessment performed at an interval of at least 28 days.
Overall response according to CA-125 was only evaluated for participants with a pre-treatment CA-125 within 3 days prior to start of any study treatment of at least twice the upper limit of normal (ULN).
|
3 days prior to Day 1 of every cycle, then every 6 weeks (Q6W) during the first year, every 3 months (Q3M) in the second and third year, every 6 months (Q6M) in the fourth year of the study (until data cutoff 07 December 2014, up to 4 years)
|
Percentage of Participants Achieving an Overall Response by RECIST Version 1.0 and/or 50% CA-125 Response Criteria
Tidsram: RECIST: Day 1, at end of Cycles 3 and 6, then every 6 cycles, at bevacizumab cessation, Q26W after cessation; CA-125: 3 days before Day 1 of every cycle, then Q6W(1st year), Q3M(2nd-3rd year), Q6M(4th year); until data cutoff 07Dec2014, up to 4 years
|
Overall response was only evaluated for participants who were evaluable according to RECIST v1.0 with a measurable disease at baseline and/or according to CA-125 with a pre-treatment CA-125 within 3 days prior to start of any study treatment of at least twice the ULN.
RECIST responders: Participants achieving an overall response of CR (disappearance of all target lesions and non-target lesions) or PR (>=30% decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions).
CA-125 responders: Participants with the value of CA-125 reduced by at least 50% and confirmed with a consecutive CA-125 assessment performed at an interval of at least 28 days.
|
RECIST: Day 1, at end of Cycles 3 and 6, then every 6 cycles, at bevacizumab cessation, Q26W after cessation; CA-125: 3 days before Day 1 of every cycle, then Q6W(1st year), Q3M(2nd-3rd year), Q6M(4th year); until data cutoff 07Dec2014, up to 4 years
|
Duration of Objective Response (DOR)
Tidsram: Day 1, at end of Cycles 3 and 6, then every 6 cycles while receiving bevacizumab, and then at bevacizumab cessation, every 26 weeks after cessation of bevacizumab until disease progression or death until data cutoff 07 December 2014, up to 4 years
|
DOR was defined as the time from the first documented response (CR or PR per RECIST v1.0), to the first documented protocol-defined disease progression (i.e., radiologically by RECIST, clinical, or symptomatic) or death, whichever occurred first.
Participants who had neither progressed nor died at the time of data cut-off (07 December 2014), or participants who were withdrawn from study, or lost to follow-up without documented progression, were censored.
RECIST responders: Participants achieving an overall response of CR (disappearance of all target lesions and non-target lesions) or PR (>=30% decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non-target lesions).
Disease progression: Natural progression or deterioration of the malignancy under study (including new sites of metastasis).
|
Day 1, at end of Cycles 3 and 6, then every 6 cycles while receiving bevacizumab, and then at bevacizumab cessation, every 26 weeks after cessation of bevacizumab until disease progression or death until data cutoff 07 December 2014, up to 4 years
|
Overall Survival (OS)
Tidsram: First administration of any study treatment until death or data cutoff 07 December 2014, up to 4 years
|
OS was defined as the time from the date of the first administration of any study treatment to the date of death, regardless of the cause of death.
Participants without the event of death were censored at the last date in the study, defined as the latest date of the following: the date of first administration of study treatment, date of last study treatment, date of last visit, or date last known to be alive.
Kaplan-Meier estimation was used for OS.
|
First administration of any study treatment until death or data cutoff 07 December 2014, up to 4 years
|
Biological Progression-free Interval
Tidsram: 3 days prior to Day 1 of every cycle, then every 6 weeks during the first year, every 3 months in the second and third year, every 6 months in the fourth year of the study (until data cutoff 07 December 2014, up to 4 years)
|
Biological progression-free interval is defined as the interval from the date of the first administration of any study treatment to the date of the first documented serial elevation of the ovarian cancer mucin CA-125.
More precisely, this is defined as the first documented increase in CA-125 levels as follows: (1) CA-125 greater than or equal to 2 times the upper level of normal (ULN) on 2 occasions at least 1 week apart (for participants with CA-125 within normal range pre-treatment) or (2) CA-125 greater than or equal to 2 times the ULN on 2 occasions at least 1 week apart (for participants with elevated CA-125 pre-treatment and initial normalization of CA-125 on-treatment) or (3) CA-125 greater than or equal to 2 times the nadir value, which is the lowest observed CA-125 value per participant on 2 occasions at least 1 week apart (for participants with elevated CA-125 pre-treatment which never normalized).
|
3 days prior to Day 1 of every cycle, then every 6 weeks during the first year, every 3 months in the second and third year, every 6 months in the fourth year of the study (until data cutoff 07 December 2014, up to 4 years)
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 december 2010
Primärt slutförande (Faktisk)
1 mars 2015
Avslutad studie (Faktisk)
1 mars 2015
Studieregistreringsdatum
Först inskickad
10 november 2010
Först inskickad som uppfyllde QC-kriterierna
10 november 2010
Första postat (Uppskatta)
11 november 2010
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
10 juni 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
3 maj 2016
Senast verifierad
1 maj 2016
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Carcinom
- Neoplasmer, körtel och epitel
- Genitala neoplasmer, hona
- Sjukdomar i det endokrina systemet
- Ovariella sjukdomar
- Adnexala sjukdomar
- Gonadal sjukdomar
- Neoplasmer i endokrina körtel
- Ovariella neoplasmer
- Karcinom, äggstocksepitel
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Antineoplastiska medel
- Tubulin modulatorer
- Antimitotiska medel
- Mitosmodulatorer
- Antineoplastiska medel, fytogena
- Antineoplastiska medel, immunologiska
- Angiogeneshämmare
- Angiogenesmodulerande medel
- Tillväxtämnen
- Tillväxthämmare
- Karboplatin
- Paklitaxel
- Bevacizumab
Andra studie-ID-nummer
- MO22923
- 2010-019525-34 (EudraCT-nummer)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Äggstockscancer
-
Ann & Robert H Lurie Children's Hospital of ChicagoOkändCystektomi | Godartade cystor Ovarian | Torsion | Maligna cystor OvarianFörenta staterna
-
Assistance Publique - Hôpitaux de ParisAktiv, inte rekryterandeOkomplicerad Tubo Ovarian AbscessFrankrike
-
Peking University Third HospitalHar inte rekryterat ännuOvarian clear cell carcinoma
-
Dansk FertilitetsklinikOkändKvinnlig infertilitet | Hypogonadism; OvarianDanmark
-
University Health Network, TorontoAvslutad
-
National University Hospital, SingaporeOkändOvarian clear cell carcinomaSingapore
-
AstraZenecaAvslutadOvarian, Äggledaren, Peritoneal cancer, P53 MutationFörenta staterna, Kanada, Nederländerna
-
M.D. Anderson Cancer CenterGSK Pharma; LixteRekryteringOvarian clear cell carcinomaFörenta staterna
-
National Taiwan University HospitalSamsung Medical Center; Chang Gung Memorial Hospital; Tokyo UniversityHar inte rekryterat ännuFIGO Steg IC2 till II Ovarian Clearcell Carcinom
-
Elizabeth K. Lee MDMerck Sharp & Dohme LLCRekryteringGynekologisk cancer | Ovarian clear cell carcinomaFörenta staterna
Kliniska prövningar på Paclitaxel
-
Nanfang Hospital of Southern Medical UniversityRekrytering
-
University of Texas Southwestern Medical CenterCelgeneAvslutadSTEG IIIA/B NSCLC / Ooperabel lungcancerFörenta staterna
-
Junling LiOkändSmåcellig lungcancer i omfattande skedeKina
-
Cook Group IncorporatedAvslutadPerifer arteriell sjukdom (PAD)Tyskland, Nya Zeeland
-
Second Affiliated Hospital, School of Medicine,...Sun Yat-sen University; Peking University International Hospital; Zhejiang...Har inte rekryterat ännuHER2-positiv bröstcancer | HjärnmetastaserKina
-
M.D. Anderson Cancer CenterCelgene CorporationAvslutadMelanom | LevermetastaserFörenta staterna
-
Rabih A. ChaerAvslutad
-
Qilu Hospital of Shandong UniversityRekryteringAvancerat gastriskt eller gastroesofagealt adenokarcinomKina
-
Shengjing HospitalRekrytering
-
Catholic University of the Sacred HeartOkänd